Literature DB >> 28979681

miR-139 acts as a tumor suppressor in T-cell acute lymphoblastic leukemia by targeting CX chemokine receptor 4.

Ling Qin1, Hui-Yang Deng1, Sheng-Jiang Chen2, Wei Wei1, Yi-Ting Zhang1.   

Abstract

MicroRNAs (miRNAs) act as tumor regulators in T-cell acute lymphoblastic leukemia (T-ALL). However, the molecular mechanisms by which miRNA-139 (miR-139) regulates T-ALL remain unclear. In this study, we found that miR-139 was lowly expressed whereas C-X-C chemokine receptor type 4 (CXCR4) was highly expressed in T-ALL cell lines and patient samples. The T-ALL patients simultaneously with high levels of CXCR4 and low expression of miR-139 possessed poor prognosis. Moreover, the introduction of miR-139 inhibited T-ALL cell proliferation and invasion in vitro and suppressed tumor growth and lung metastasis in vivo. CXCR4 was identified as a direct target of miR-139. The suppressive effects of miR-139 were mimicked and counteracted by CXCR4 depletion and overexpression, respectively. Overall, the miR-139/CXCR4 axis plays an important role in T-ALL carcinogenesis.

Entities:  

Keywords:  CXCR4; T-ALL; miR-139

Year:  2017        PMID: 28979681      PMCID: PMC5622250     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  30 in total

1.  HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells.

Authors:  Wei Bao; Hai-Jing Fu; Qiao-Sheng Xie; Lei Wang; Rui Zhang; Zhang-Yan Guo; Jing Zhao; Yan-Ling Meng; Xin-Ling Ren; Tao Wang; Qing Li; Bo-Quan Jin; Li-Bo Yao; Rui-An Wang; Dai-Ming Fan; Si-Yi Chen; Lin-Tao Jia; An-Gang Yang
Journal:  Gastroenterology       Date:  2011-09-16       Impact factor: 22.682

2.  MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells.

Authors:  Hua-Nan Luo; Zheng-Hui Wang; Ying Sheng; Qing Zhang; Jing Yan; Jin Hou; Kang Zhu; Ying Cheng; Ying-Long Xu; Xiang-Hong Zhang; Min Xu; Xiao-Yong Ren
Journal:  Med Oncol       Date:  2013-12-07       Impact factor: 3.064

3.  CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.

Authors:  Diana Passaro; Marta Irigoyen; Claire Catherinet; Stéphanie Gachet; Cindy Da Costa De Jesus; Charlène Lasgi; Christine Tran Quang; Jacques Ghysdael
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

4.  Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.

Authors:  Konstantinos J Mavrakis; Andrew L Wolfe; Elisa Oricchio; Teresa Palomero; Kim de Keersmaecker; Katherine McJunkin; Johannes Zuber; Taneisha James; Aly A Khan; Christina S Leslie; Joel S Parker; Patrick J Paddison; Wayne Tam; Adolfo Ferrando; Hans-Guido Wendel
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

5.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Authors:  John M Goldberg; Lewis B Silverman; Donna E Levy; Virginia Kimball Dalton; Richard D Gelber; Leslie Lehmann; Harvey J Cohen; Stephen E Sallan; Barbara L Asselin
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

6.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

7.  Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

Authors:  Elwin J C Rombouts; Biljana Pavic; Bob Löwenberg; Rob E Ploemacher
Journal:  Blood       Date:  2004-03-30       Impact factor: 22.113

8.  The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.

Authors:  Yuan-Yeh Kuo; Hsin-An Hou; Yin-Kai Chen; Li-Yu Li; Po-Hsuen Chen; Mei-Hsuan Tseng; Chi-Fei Huang; Fen-Yu Lee; Ming-Chih Liu; Chia-Wen Liu; Wen-Chien Chou; Chieh-Yu Liu; Jih-Luh Tang; Ming Yao; Hwei-Fang Tien
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

9.  MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia.

Authors:  K Krowiorz; J Ruschmann; C Lai; M Ngom; T Maetzig; V Martins; A Scheffold; E Schneider; N Pochert; C Miller; L Palmqvist; A Staffas; M Mulaw; S R Bohl; C Buske; M Heuser; J Kraus; K O'Neill; C L Hansen; O I Petriv; H Kestler; H Döhner; L Bullinger; K Döhner; R K Humphries; A Rouhi; F Kuchenbauer
Journal:  Blood Cancer J       Date:  2016-12-09       Impact factor: 11.037

10.  CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.

Authors:  Lauren A Pitt; Anastasia N Tikhonova; Hai Hu; Thomas Trimarchi; Bryan King; Yixiao Gong; Marta Sanchez-Martin; Aris Tsirigos; Dan R Littman; Adolfo A Ferrando; Sean J Morrison; David R Fooksman; Iannis Aifantis; Susan R Schwab
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

View more
  6 in total

1.  Growth arrest-specific protein 2 (GAS2) interacts with CXCR4 to promote T-cell leukemogenesis partially via c-MYC.

Authors:  Wenjuan Ma; Yan Wan; Jianxiang Zhang; Jianan Yao; Yifei Wang; Jinchang Lu; Hong Liu; Xiaorui Huang; Xiuyan Zhang; Haixia Zhou; Yulong He; Depei Wu; Jianrong Wang; Yun Zhao
Journal:  Mol Oncol       Date:  2022-09-11       Impact factor: 7.449

2.  Verification of candidate microRNA markers for parathyroid carcinoma.

Authors:  Ya Hu; Xiang Zhang; Ming Cui; Zhe Su; Mengyi Wang; Quan Liao; Yupei Zhao
Journal:  Endocrine       Date:  2018-02-16       Impact factor: 3.633

3.  Reduced expression of microRNA-139-5p in hepatocellular carcinoma results in a poor outcome: An exploration the roles of microRNA-139-5p in tumorigenesis, advancement and prognosis at the molecular biological level using an integrated meta-analysis and bioinformatic investigation.

Authors:  Hui Qin; Dong-Yue Wen; Qiao Que; Chuan-Yang Zhou; Xiao-Dong Wang; Yu-Ting Peng; Yun He; Hong Yang; Bo-Ming Liao
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

Review 4.  Targeting chemokines for acute lymphoblastic leukemia therapy.

Authors:  Zixi Hong; Zimeng Wei; Tian Xie; Lin Fu; Jiaxing Sun; Fuling Zhou; Muhammad Jamal; Qiuping Zhang; Liang Shao
Journal:  J Hematol Oncol       Date:  2021-03-20       Impact factor: 17.388

5.  H19 Overexpression Improved Efficacy of Mesenchymal Stem Cells in Ulcerative Colitis by Modulating the miR-141/ICAM-1 and miR-139/CXCR4 Axes.

Authors:  Ming-Li Zhao; Tao Chen; Teng-Hui Zhang; Feng Tian; Xiao Wan
Journal:  Dis Markers       Date:  2021-09-29       Impact factor: 3.434

Review 6.  MicroRNA-139, an Emerging Gate-Keeper in Various Types of Cancer.

Authors:  Christiaan J Stavast; Iris van Zuijen; Stefan J Erkeland
Journal:  Cells       Date:  2022-02-22       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.